MedTrace Logo

BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration.

NCT00668057 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 624

Last updated 2015-03-06

No results posted yet for this study

Summary

This study was to compare the efficacy of 3 doses of vardenafil, 5 mg, 10 mg and 20 mg, with matching placebo in Chinese male ED patients, treated for a maximum of 12 weeks.

Conditions

Interventions

DRUG

Levitra (Vardenafil, BAY38-9456)

5 mg Vardenafil orally 1 hour prior to sexual intercourse

DRUG

Levitra (Vardenafil, BAY38-9456)

10 mg Vardenafil orally 1 hour prior to sexual intercourse

DRUG

Levitra (Vardenafil, BAY38-9456)

20 mg Vardenafil orally 1 hour prior to sexual intercourse

DRUG

Placebo

5 mg matching placebo

DRUG

Placebo

10 mg matching placebo

DRUG

Placebo

20 mg matching placebo

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2003-09-30
Completion
2003-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00668057 on ClinicalTrials.gov